Periostin as Injectable Therapeutic for Heart Failure
Inventors: Bernhard Kuhn
Invention Types: Therapeutics
Research Areas: Cardiovascular/Cardiology, Regenerative Medicine
Keywords: Large Molecule, Peptide, ProteinFor More Information Contact: Miracco, Amy
The invention describes the use of periostin to stimulate differentiated cardiomyocyte proliferation. In vitro delivery of periostin induced adult cardiomyocytes to undergo cell cycle and proliferate, an effect that was specific for cardiomyocytes and not inducible by other cell cycle stimulating factors.
Effects of periostin were also demonstrated in vivo in myocardial infracted rats. Rats treated with a periostin-impregnated Gelfoam patch exhibited improved ventricular remodeling and cardiac function; detailed analysis of periostin-treated rat hearts showed increased ventricular wall thickness, thinner septum, less cellular hypertrophy, and after 12 weeks, a smaller scar volume. Although apoptosis of myocardial cells was evident in periostin-treated rats, an increased number of adult cardiomyocytes undergoing cell cycle was also exhibited in these rats, a result consistent with in vitro data and indicative that cardiomyocyte proliferation accounted for the improved cardiac function.
Treatment of cardiomyocytes with periostin could be used to improve patient outcome after heart attack and rebuild heart tissue. Periostin therapy may limit the amount of damage to the heart after myocardial infarction and enhance cardiomyocyte proliferation resulting in rebuilding heart tissue and improving cardiac function.
Periostin has a direct affect on cardiomyocytes and not other cell types such as fibroblasts. Periostin can be delivered in a controlled manner to stimulate cardiomyocyte proliferation and cardiac repair over a prolonged time period.
License, Start-up company, Sponsored Research
Key Publications: Nat. Med. 2007 8:962-9; PLoS ONE 2012 7(5): e36788
Related Publications: PCT: WO 2008/091867
IPStatus: Pat. Pend.